Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: A pediatric experience

Pediatric Transplantation

Volumn 13, Issue 7, 2009, Pages 923-926

  Faraci, M ^a   Cappelli, B ^a   Lanino, E ^a   Morreale, G ^a   Fioredda, F ^a   Giudice, C L ^b   Giacchino, R ^c  

^a Bone Marrow Transplant Unit   (Italy)

^b Transfusion Service   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Children; HBV reactivation; HSCT

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LAMIVUDINE; STEROID; THIOTEPA; VIRUS DNA;

ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHILD; EASTERN EUROPE; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PERSISTENT VIRUS INFECTION; SCHOOL CHILD; VIRUS REACTIVATION;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; LIVER DISEASES; MALE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 70349950590     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.01080.x     Document Type: Article

References (22)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004 : 11 : 97 107.
2. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007 : 136 : 699 712.
3. El-Sayed MH, Shanab G, Karim AM, El-Tawil A, Black A, Dixon JS. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with haematological malignancies: A preliminary report. Pediatr Hematol Oncol 2004 : 21 : 145 156.
4. Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003 : 25 : 184 192.
5. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat 2008 : 15 : 89 102.
6. Gish RG, Locarnini SA. Chronic hepatitis B: Current testing strategies. Clin Gastroenterol Hepatol 2006 : 4 : 666 676.
7. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006 : 43 : S173 S181.
8. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002 : 99 : 2324 2330.
9. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987 : 92 : 1839 1843.
10. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study. J Med Virol 2003 : 70 : 553 561.
11. Ciesek S, Helfrits FA, Lehmann U, et al. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis 2008 : 197 : 355 360.
12. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007 : 39 : 397 408.
13. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 : 132 : 931 937.
14. Lykavieris P, Fabre M, Yvart J, Alvarez F. HBV infection in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1993 : 16 : 321 327.
15. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005 : 55 : 828 831.
16. Li Y, He Y, Jiang W, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006 : 106 : 1320 1325.
17. Jonas MM, Kelley DA, Mizerski J, et al. International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002 : 346 : 1706 1713.
18. Hagmann S, Chung M, Rochford G, et al. Response to lamivudine treatment in children with chronic hepatitis B virus infection. Clin Infect Dis 2003 : 37 : 1434 1440.
19. Yeung LT, Petric M, Cutz E, Roberts EA. Histological improvement with lamivudine therapy for de novo hepatitis B occurring in an anti-HBs-positive child after bone marrow transplantation. Bone Marrow Transplant 2002 : 30 : 459 462.
20. Shapira R, Mor E, Bar-Nathan N, et al. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children. Transplantation 2001 : 27 : 333 336. (Pubitemid 32729358)
21. Tavil B, Kuşkonmaz B, Kasem M, Demir H, Cetin M, Uçkan D. Hepatitis B immunoglobulin in combination with lamivudine for prevention of hepatitis B virus reactivation in children undergoing bone marrow transplantation. Pediatr Transplant 2006 : 10 : 966 969.
22. Barclay S, Pol S, Mutimer D, et al. The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. J Clin Virol 2008 : 41 : 243 254.